| Trial ID: | L2756 |
| Source ID: | NCT05996380
|
| Associated Drug: |
Shr-3167
|
| Title: |
A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
T2DM
|
| Interventions: |
DRUG: SHR-3167|DRUG: SHR-3167 Placebo
|
| Outcome Measures: |
Primary: Safety endpoints: Number of Adverse Events, A summary of adverse events, including Serious Adverse Events(SAEs), Start of Treatment to end of study (approximately 92 days) |
|
| Sponsor/Collaborators: |
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
52
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2023-06-09
|
| Completion Date: |
2024-04-28
|
| Results First Posted: |
|
| Last Update Posted: |
2023-10-11
|
| Locations: |
Jiangsu Province Hospital, Nanjing, Jiangsu, 210029, China
|
| URL: |
https://clinicaltrials.gov/show/NCT05996380
|
